Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ML-055
- Development stage
- Preclinical
- Lead developer
- MapLight Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular, Subcutaneous
01
Overview
ML-055 is a next-generation small molecule agonist of the M1 and M4 muscarinic acetylcholine receptors, currently under development by MapLight Therapeutics for the treatment of various neuropsychiatric conditions. Utilizing MapLight's proprietary circuit-based discovery platform, ML-055 is designed to modulate both the direct and indirect neural pathways to alleviate symptoms associated with disorders such as schizophrenia and Alzheimer's disease psychosis. The program aims to improve upon the profile of first-generation muscarinic agonists, such as ML-007, by offering significantly enhanced potency and the potential for optimized delivery formats, including once-daily oral administration or long-acting injectable (LAI) formulations. As of early 2026, ML-055 is in the preclinical stage, with the company working toward the nomination of a formal development candidate to advance into IND-enabling studies.
- Other names
- M1/M4 muscarinic agonist program
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM4 (M4)
Beyond the preview
Go deeper on ML-055.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ML-055.